News Archive Egalet Receives Complete Response Letter from U.S. Food and Drug Administration for Prior Approval Supplement for 10 mg and 15 mg Dosage Strengths of OXAYDO Tue, 20 Jun 2017 09:06:00 -0400 Egalet Partners with Ascend Therapeutics® U.S., LLC to Co-Promote SPRIX® Nasal Spray -- 37 Ascend Therapeutics women's health specialty sales representatives to call on 9,000 women's healthcare practitioners -- Wed, 07 Jun 2017 06:02:00 -0400 Egalet Announces ARYMO® ER Added to Large Payer Formulary Tue, 06 Jun 2017 06:02:00 -0400 Egalet Announces Issuance of New U.S. Patent for Guardian™ Technology -- Patent covers combination products with precise drug delivery properties -- Mon, 05 Jun 2017 06:02:00 -0400 Egalet Announces Results of ARYMO® ER Harm Reduction Modeling Analysis -Results suggest that replacement of non-abuse-deterrent, extended-release morphine with ARYMO ER could lead to potential reductions in opioid abuse-related events- Thu, 18 May 2017 16:02:00 -0400